C Caranobe|P Sie|B Boneu - JoVE Visualize

Showing results (41-50 of 179) with videos related to

Pageof 18

Sort By:

European Journal of Clinical Investigation|December 1, 1985

Platelet alpha 2 adrenoceptors in Parkinson's disease: decreased number in untreated patients and recovery after treatmentA Villeneuve, M Berlan, M Lafontan, et al.

Thrombosis and Haemostasis|April 22, 1985

Platelet regeneration time after aspirin ingestion and platelet survival time after labelling with 51chromium or 111indium oxine--a comparative studyA Boneu, P Sié, R Bugat, et al.

Thrombosis Research|September 15, 1986

Heparin fractions with high and low affinities to antithrombin III are cleared at different ratesC Caranobe, M Petitou, D Dupouy, et al.

Archives Des Maladies Du Coeur Et Des Vaisseaux|September 1, 1985

[Myocardial infarct of effort with normal coronaries. Study of in vivo platelet activation]P Douste-Blazy, P Sie, B Fontan, et al.

British Journal of Haematology|December 1, 1986

Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharidesP Sie, F Ofosu, F Fernandez, et al.

European Journal of Cancer & Clinical Oncology|July 1, 1984

Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathyB Boneu, R Bugat, A Boneu, et al.

Blood|November 8, 2001

Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in menY Cadroy, K S Sakariassen, J P Charlet, et al.

Thrombosis Research|October 15, 1988

Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological propertiesF Dol, C Caranobe, D Dupouy, et al.

Thrombosis and Haemostasis|April 8, 1988

Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does notY Cadroy, F Dol, C Caranobe, et al.

Thrombosis and Haemostasis|March 2, 1992

Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effectsS Saivin, M Petitou, J C Lormeau, et al.

Pageof 18

Showing results (41-50 of 179) with videos related to

Sort By:

Pageof 18

European Journal of Clinical Investigation|December 1, 1985

Platelet alpha 2 adrenoceptors in Parkinson's disease: decreased number in untreated patients and recovery after treatmentA Villeneuve, M Berlan, M Lafontan, et al.

Thrombosis and Haemostasis|April 22, 1985

Platelet regeneration time after aspirin ingestion and platelet survival time after labelling with 51chromium or 111indium oxine--a comparative studyA Boneu, P Sié, R Bugat, et al.

Thrombosis Research|September 15, 1986

Heparin fractions with high and low affinities to antithrombin III are cleared at different ratesC Caranobe, M Petitou, D Dupouy, et al.

Archives Des Maladies Du Coeur Et Des Vaisseaux|September 1, 1985

[Myocardial infarct of effort with normal coronaries. Study of in vivo platelet activation]P Douste-Blazy, P Sie, B Fontan, et al.

British Journal of Haematology|December 1, 1986

Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharidesP Sie, F Ofosu, F Fernandez, et al.

European Journal of Cancer & Clinical Oncology|July 1, 1984

Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathyB Boneu, R Bugat, A Boneu, et al.

Blood|November 8, 2001

Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in menY Cadroy, K S Sakariassen, J P Charlet, et al.

Thrombosis Research|October 15, 1988

Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological propertiesF Dol, C Caranobe, D Dupouy, et al.

Thrombosis and Haemostasis|April 8, 1988

Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does notY Cadroy, F Dol, C Caranobe, et al.

Thrombosis and Haemostasis|March 2, 1992

Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effectsS Saivin, M Petitou, J C Lormeau, et al.

Pageof 18